Prevention of sodium valproate-induced hepatotoxicity by curcumin, rosiglitazone and N-acetylcysteine in rats

Abstract

The present study was designed to examine the potential preventive effect of curcumin (CMN; CAS 458-37-7), rosiglitazone (RGN; CAS 155141-29-0), N-acetylcysteine (NAC; CAS 616-91-1), resveratrol (RSV; CAS 501-36-0), and losartan (LOS; CAS 114798-26-4) on sodium valproate-induced hepatotoxicity. Sodium valproate (SVP; CAS 1069-66-5) was given at a dose of 250 mg/kg i. p. 3 times daily for one week. The tested compounds were given simultaneously with SVP for one week. The results demonstrate that CMN, RGN and NAC treatment can confer protection from SVP-induced hepatotoxicity. The second part of the study includes an evaluation of the effect of CMN, RGN and NAC on the anticonvulsant activity of SVP against pentetrazole-induced seizures in mice. The results demonstrate that CMN, RGN and NAC do not affect the anticon-vulsant activity of SVP. Combined administration of either of CMN, RGN and NAC with valproate appears to be beneficial in reducing valproate-induced hepatotoxicity.

Key words

N-Acetylcysteine - Curcumin - Hepatotoxicity - Losartan - Resveratrol - Rosiglitazone - Valproate

• References

• 1 Wong H, Rurak DW, Kumar S, Kwan E, Abbott FS, Wayne Riggs K. Dose-dependent pharmacokinetics and metabolism of valproic acid in newborn lambs and adult sheep. Drug Metab Dispos. 2001; 29 (5) 664-75
• 2 Löscher W. Basic pharmacology of valproate. A review after 35 years of clinical use for the treatment of epilepsy. CNS Drugs. 2002; 16 (10) 669-94
• 3 Bryant AE, Dreifuss FE. Valproic acid hepatic fatalities III US experience since 1986. Neurology. 1996; 46 (2) 465-9
• 4 Jeavons PM. Non-dose-related side effects of valproate. Epilepsia. 1984; 25: S50-6
• 5 Dreifuss FE, Santilli N, Langer DH, Sweeney KP, Moline KA, Menander KB. Valproic acid hepatic fatalities: a retrospective review. Neurology. 1987; 37 (3) 379-85
• 6 Tong V, Teng XW, Chang TK, Abbott FS. Valproic acid I: time course of lipid peroxidation biomarkers, liver toxicity, and valproic acid metabolite levels in rats. Toxicol Sci. 2005; 86 (2) 427-35
• 7 Kassahun K, Abbott F. In vivo formation of the thiol conjugates of reactive metabolites of 4-ene VPA and its analog 4-pentenoic acid. Drug Metab Dispos. 1993; 21 (6) 1098-106
• 8 Raza M, Al-Bekairi AM, Ageel AM, Qureshi S. Biochemical basis of sodiumvalproate hepatotoxicity and renal tubular disorder: time dependence of peroxidative injury. Pharmacol Res. 1997; 35 (2) 153-7
• 9 Tong V, Teng XW, Chang TK, Abbott FS. Valproic acid II: effects on oxidative stress, mitochondrial membrane potential, and cytotoxicity in glutathione-depleted rat hepatocytes. Toxicol Sci. 2005; 86 (2) 436-43
• 10 Löscher W, Wahnschaffe U, Honack D, Wiltfoht W, Nau H. Effect of valproate and E-2-en-valproate on functional and morphological parameters of rat liver;I. Biochemical histopathological and pharmacokinetic studies. Epilepsy Res. 1992; 13 (3) 187-98
• 11 Shapiro H, Ashkenazi M, Weizman N, Shahmurov M, Aeed H, Bruck R. Curcumin ameliorates acute thioacetamide-induced hepatotoxicity. J Gastroenterol Hepatol. 2006; 21 (2) 358-66
• 12 Sengottuvelan M, Viswanathan P, Nalini N. Chemopreventive effect of trans-resveratrol – a phytoalexin against colonic aberrant crypt foci and cell proliferation in 1,2-di-methylhydrazine induced colon carcinogenesis. Carcinogenesis. 2006; 27 (5) 1038-46
• 13 Galli A, Crabb DW, Ceni E, Salzano R, Mello T, Svegliati-Baroni G et al. Antidiabetic thiazolidinediones inhibit collagen synthesis and hepatic stellate cell activation in vivo and in vitro . Gastroenterology. 2002; 122 (7) 1924-40
• 14 Wei HS, Li DG, Lu HM, Zhan Y-T, Wang ZR, Huang X et al. Effects of AT1 receptor antagonist, losartan, on rat hepatic fibrosis induced by CC1₄ . World J Gastroenterol. 2000; 6 (4) 540-5
• 15 Cetinkaya A, Bulbuloglu E, Kurutas EB, Kantarceken B. N-acetylcysteine ameliorates methotrexate-induced oxidative liver damage in rats. Med Sci Monit. 2006; 12 (8) 274-8
• 16 Vohora D, Pal SN, Pillai KK. Thioperamide, a selective histamine H₃ receptor antagonist protects against PTZ-induced seizures in mice. Life Sci. 2000; 66 (22) 297-301
• 17 DeVane CL. Pharmacokinetics, drug interactions and tolerability of valproate. Psychopharmacol Bull. 2003; 37: S25-42
• 18 Ukil A, Maity S, Karmakar S, Datta N, Vedasiromoni JR, Das PK. Curcumin, the major component of food flavour turmeric, reduces mucosal injury in trinitrobenzene sulphonic acid-induced colitis. Br J Pharmacol. 2003; 139 (2) 209-18
• 19 Ryan MJ, Didion SP, Mathur S, Faraci FM, Sigmund CD. PPAR-γ agonist rosiglitazone improves vascular function and lowers blood pressure in hypertensive transgenic mice. Hypertension. 2004; 43 (3) 661-6
• 20 Uma Devi P, Pillai KK, Vohora D. Modulation of pentylene-tetrazole-induced seizures and oxidative stress parameters by sodium valproate in the absence and presence of Nacetylcysteine. Fundam Clin Pharmacol. 2006; 20 (3) 247-53
• 21 Kassahun K, Hu P, Grillo MP, Davis MR, Jin L, Baillie TA. Metabolic activation of unsaturated derivatives of valproic acid. Identification of novel glutathione adducts formed through coenzyme A-dependent and -independent processes. Chem Biol Interact. 1994; 90 (3) 253-75
• 22 Farrell K, Abbott FS. Role of N-acetylcysteine in the treatment of valproate hepatotoxicity. In: Levy RH, Penry JK. editors. Idiosyncratic Reactions to Valproate: Clinical Risk Patterns and Mechanisms of Toxicity. New York: Raven Press; 1991. p. 149-153
• 23 Tong V, Chang TK, Chen J, Abbot FS. The effect of valproic acid on hepatic and plasma levels of 15-F2t-isoprostane in rats. Free Radic Biol Med. 2003; 34 (11) 1435-46
• 24 Nanji AA, Jokelainen K, Tipoe GL, Rahemtulla A, Thomas P, Dannenberg AJ. Curcumin prevents alcohol-induced liver disease in rats by inhibiting the expression of NF-kappa B-dependent genes. Am J Physiol. 2003; 284 (2) G321-7
• 25 Asai A, Miyazawa T. Dietary curcuminoids prevent high-fat diet induced lipid accumulation in rat liver and epididymal adipose tissue. J Nutr. 2001; 131 (11) 2932-2935
• 26 Leclercq IA, Farrell GC, Sempoux C, dela-Pena A, Horsmans YJ. Curcumin inhibits NF-kappaB activation and reduces the severity of experimental steatohepatitis in mice. J Hepatol. 2004; 41 (6) 926-34
• 27 Kamalakkannan N, Rukkumani R, Varma PS, Viswanathan P, Rajasekharan KN, Menon VP. Comparative effects of curcumin and an analogue of curcumin in carbon tetrachloride-induced hepatotoxicity in rats. Basic Clin Pharmacol Toxicol. 2005; 97 (1) 15-21
• 28 Wei QY, Chen WF, Zhou B, Yang L, Liu ZL. Inhibition of lipid peroxidation and protein oxidation in rat liver mitochondria by curcumin and its analogues. Biochim Biophys Acta. 2006; 1760 (1) 70-7
• 29 Zheng S, Yumei F, Chen A. de novo synthesis of glutathione is a prerequisite for curcumin to inhibit HSC activation. Free Radic Biol Med. 2007; 43 (3) 444-53
• 30 Reyes-Gordillo K, Segovia J, Shibayama M, Vergara P, Moreno MG, Muriel P. Curcumin protects against acute liver damage in the rat by inhibiting NF-kB, proinflammatory cytokines production and oxidative stress. Biochim Biophy Acta. 2007; 1770 (6) 989-96
• 31 Nishinaka T, Ichijo Y, Ito M, Kimura M, Katsuyama M, Iwata K et al. Curcumin activates human glutathione-S-transferase P1 expression through antioxidant response element. Toxicol Lett. 2007; 170 (3) 238-47
• 32 Reynaert H, Geerts A, Henrion J. Review article: the treatment of non-alcoholic steatohepatitis with thiazolidinediones. Aliment Pharmacol Ther. 2005; 22 (10) 897-905
• 33 Elte JW, Blicklé JF. Thiazolidinediones for the treatment of type 2 diabetes. Eur J Intern Med. 2007; 18 (1) 18-25
• 34 Henriksen JH, Ring-Larsen H. Rosiglitazone: possible complications and treatment of non-alcoholic steatohepatitis (NASH). J Hepatol. 2008; 48 (1) 174-6
• 35 Neuschwander-Tetri BA, Brunt EM, Wehmeier KR, Oliver D, Bacon BR. Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone. Hepatology. 2003; 38 (4) 1008-17
• 36 Neuschwander-Tetri BA, Brunt EM, Wehmeier KR, Sponseller CA, Hampton K, Bacon BR. Interim results of a pilot study demonstrating the early effects of the PPAR-γ ligand rosiglitazone on insulin sensitivity, aminotransferases, hepatic steatosis and body weight in patients with non-alcoholic steatohepatitis. J Hepatol. 2003; 38 (4) 434-40
• 37 Memon RA, Tecott LH, Nonogaki K, Beigneux A, Moser AH, Grunfeld C et al. Up-regulation of peroxisome proliferator-activated receptors (PPAR-alpha) and PPARgamma messenger ribonucleic acid expression in the liver in murine obesity: troglitazone induces expression of PPAR-gamma-responsive adipose tissue-specific genes in the liver of obese diabetic mice. Endocrinology. 2000; 141 (11) 4021-31
• 38 Kawaguchi K, Sakaida I, Tsuchiya M, Omori K, Takami T, Okita K. Pioglitazone prevents hepatic steatosis, fibrosis, and enzyme-altered lesions in rat liver cirrhosis induced by a choline-deficient L-amino acid-defined diet. Biochem Biophys Res Commun. 2004; 315 (1) 187-95
• 39 Uto H, Nakanishi C, Ido A, Hasuike S, Kusumoto K, Abe H. The peroxisome proliferator-activated receptor-γ agonist, pioglitazone, inhibits fat accumulation and fibrosis in the livers of rats fed a choline-deficient, L-amino acid-defined diet. Hepatol Res. 2005; 32 (4) 235-42
• 40 Xu P, Zhang XG, Li YM, Yu CH, Xu L, Xu GY. Research on the protection effect of pioglitazone for non-alcoholic fatty liver disease (NAFLD) in rats. J Zhejiang Univ Sci B. 2006; 7 (8) 627-33
• 41 Leclercq IA, Lebrun VA, Stärkel P, Horsmans YJ. Intrahepatic insulin resistance in a murine model of steatohepatitis: effect of PPAR-γ agonist pioglitazone. Lab Invest. 2007; 87 (1) 56-65
• 42 Tahan V, Eren F, Avsar E, Yavuz D, Yuksel M, Emekli E et al. Rosiglitazone attenuates liver inflammation in a rat model of non-alcoholic steatohepatitis. Dig Dis Sci. 2007; 52 (12) 3465-72
• 43 Yki-Järvinen H. Thiazolidinediones. N Engl J Med. 2004; 351 (11) 1106-18
• 44 Fryer LG, Parbu-Patel A, Carling D. The antidiabetic drugs rosiglitazone and metformin stimulate AMP-activated protein kinase through distinct signaling pathways. J Biol Chem. 2002; 277 (28) 25226-32
• 45 Donnelly LE, Newton R, Kennedy G E, Fenwick PS, Leung RH, Ito K et al. Anti-inflammatory effects of resveratrol in lung epithelial cells: molecular mechanisms. Am J Physiol. 2004; 287 (4) L774-83
• 46 Wolter F, Ulrich S, Stein J. Molecular mechanisms of the chemopreventive effects of resveratrol and its analogues in colorectal cancer: key role of polyamines?. J Nutr. 2004; 134 (12) 3219-22
• 47 Cai YJ, Fang JG, Ma LP, Yang L, Liu ZL. Inhibition of free radical-induced peroxidation of rat liver microsomes by resveratrol and its analogues. Biochim Biophys Acta. 2003; 1637 (1) 31-8
• 48 Yokohama S, Yoneda M, Haneda M, Okamoto S, Okada M, Aso K et al. Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steato-hepatitis. Hepatology. 2004; 40 (5) 1222-5
• 49 Aruoma OI, Halliwell B, Hoey BM, Bulter J. The antioxidant action of N-acetylcysteine: its reaction with hydrogen peroxide, hydroxyl radical, superoxide, and hypochlorous acid. Free Radic Biol Med. 1989; 6 (6) 593-7
• 50 Cotgreave IA. N-Acetylcysteine: pharmacological considerations and experimental and clinical applications. Adv Pharmacol. 1997; 38: 205-27
• 51 Federico A, Trappoliere M, Loguercio C. Treatment of patients with non-alcoholic fatty liver disease: current views and perspectives. Dig Liver Dis. 2006; 38 (11) 789-801